{"id":57148,"date":"2026-02-14T11:13:30","date_gmt":"2026-02-14T03:13:30","guid":{"rendered":"https:\/\/flcube.com\/?p=57148"},"modified":"2026-02-14T11:13:31","modified_gmt":"2026-02-14T03:13:31","slug":"genhouse-bio-partners-with-gilead-on-1-5-billion-synthetic-lethal-cancer-project-gh31","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57148","title":{"rendered":"Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31"},"content":{"rendered":"\n

Genhouse Bio (Suzhou) Co., Ltd.<\/strong>, a Viva Biotech-incubated company<\/strong>, announced a global collaboration agreement<\/strong> with Gilead Sciences, Inc.<\/strong> (NASDAQ:\u202fGILD<\/a><\/strong>) for GH31<\/strong>, its MAT2A-targeting synthetic lethal anti-tumor therapy<\/strong>. The deal, valued at up to USD\u202f1.53 billion<\/strong>, grants Gilead exclusive global rights<\/strong> to develop and commercialize the biomarker-driven oncology asset<\/strong>, which has received IND approvals in both the US and China<\/strong> and is ready for immediate global clinical development<\/strong>.<\/p>\n\n\n\n

Transaction Structure<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Biotech Partner<\/strong><\/td>Genhouse Bio (Suzhou) Co., Ltd. (Viva Biotech portfolio company)<\/td><\/tr>
Pharma Partner<\/strong><\/td>Gilead Sciences, Inc. (NASDAQ:\u202fGILD)<\/td><\/tr>
Asset<\/strong><\/td>GH31 \u2013 MAT2A-targeting synthetic lethal therapy<\/td><\/tr>
Mechanism<\/strong><\/td>Synthetic lethality<\/strong> \u2013 biomarker-driven tumor cell killing<\/td><\/tr>
IND Status<\/strong><\/td>Approved in US and China<\/strong> \u2013 ready for global clinical development<\/td><\/tr>
Rights Granted<\/strong><\/td>Exclusive global development and commercialization<\/strong><\/td><\/tr>
Upfront Payment<\/strong><\/td>USD\u202f80 million<\/strong><\/td><\/tr>
Milestone Potential<\/strong><\/td>Up to USD\u202f1.45 billion<\/strong> (development, regulatory, commercialization)<\/td><\/tr>
Royalties<\/strong><\/td>Tiered double-digit percentages<\/strong> on net sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Target Biology & Therapeutic Rationale<\/h2>\n\n\n\n
Feature<\/th>GH31 Specification<\/th>Strategic Value<\/th><\/tr><\/thead>
Target<\/strong><\/td>MAT2A (methionine adenosyltransferase 2A)<\/strong><\/td>Synthetic lethal vulnerability<\/strong> in MTAP-deleted tumors<\/strong> (~15% of all cancers)<\/td><\/tr>
Mechanism<\/strong><\/td>Biomarker-driven synthetic lethality<\/strong><\/td>Precision oncology approach<\/strong>; tumor-selective killing<\/strong> with minimal normal tissue toxicity<\/strong><\/td><\/tr>
Tumor Types<\/strong><\/td>Multiple indications<\/strong> \u2013 lung, pancreatic, bladder, glioblastoma<\/td>Broad applicability<\/strong> across high-unmet-need malignancies<\/strong><\/td><\/tr>
Biomarker<\/strong><\/td>MTAP deletion<\/strong> (methylthioadenosine phosphorylase)<\/td>Companion diagnostic opportunity<\/strong>; patient selection for optimal efficacy<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Positioning & Industry Context<\/h2>\n\n\n\n
Factor<\/th>Strategic Analysis<\/th><\/tr><\/thead>
Synthetic Lethality Validation<\/strong><\/td>PARP inhibitors (olaparib)<\/strong> validated synthetic lethal mechanism<\/strong> in BRCA-mutant cancers<\/strong>; MAT2A represents next-wave target<\/strong> with larger addressable population<\/strong><\/td><\/tr>
Gilead Oncology Strategy<\/strong><\/td>Trodelvy (sacituzumab govitecan)<\/strong> established in solid tumors<\/strong>; GH31 adds precision oncology<\/strong> with biomarker-driven development<\/strong>; complements cell therapy and ADC platforms<\/strong><\/td><\/tr>
Genhouse\/Viva Biotech Model<\/strong><\/td>Incubator\/accelerator success story<\/strong> \u2013 Viva Biotech’s CRO\/CMC platform<\/strong> de-risks early development; Gilead partnership validates<\/strong> China-origin innovation<\/strong><\/td><\/tr>
Global Development Ready<\/strong><\/td>Dual US-China IND approval<\/strong> enables parallel Phase I execution<\/strong>; accelerated timeline<\/strong> vs. traditional sequential regulatory pathways<\/strong><\/td><\/tr>
Competitive Landscape<\/strong><\/td>Agios (MAT2A inhibitor, phase 1)<\/strong>; IdeeYa (MAT2A PRMT5 synthetic lethal)<\/strong>; GH31 differentiation<\/strong> via biomarker optimization<\/strong> and Gilead development expertise<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development Roadmap<\/h2>\n\n\n\n
Phase<\/th>Activity<\/th>Responsible Party<\/th>Timeline<\/th><\/tr><\/thead>
Current<\/strong><\/td>Partnership execution; technology transfer<\/td>Genhouse \u2192 Gilead<\/td>Q1\u202f2026<\/td><\/tr>
Clinical<\/strong><\/td>Global Phase I initiation<\/strong> (US and China sites)<\/td>Gilead<\/td>2026<\/td><\/tr>
Expansion<\/strong><\/td>Biomarker-selected patient cohorts; combination studies<\/td>Gilead<\/td>2026-2027<\/td><\/tr>
Regulatory<\/strong><\/td>Breakthrough therapy designation pursuit; Phase II\/III planning<\/td>Gilead<\/td>2027-2028<\/td><\/tr>
Commercial<\/strong><\/td>Global launch preparation; companion diagnostic partnership<\/td>Gilead<\/td>2029+<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding GH31 clinical development success, synthetic lethality mechanism validation in MAT2A-deleted tumors, and Gilead’s global commercialization execution. Actual results may differ due to Phase I safety outcomes, biomarker testing adoption, and competitive dynamics with other MAT2A inhibitors.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Genhouse Bio (Suzhou) Co., Ltd., a Viva Biotech-incubated company, announced a global collaboration agreement with…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4529,226,1025],"class_list":["post-57148","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-genhouse-bio","tag-gilead-sciences","tag-nasdaq-gild"],"yoast_head":"\nGenhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Genhouse Bio (Suzhou) Co., Ltd., a Viva Biotech-incubated company, announced a global collaboration agreement with Gilead Sciences, Inc. (NASDAQ:\u202fGILD) for GH31, its MAT2A-targeting synthetic lethal anti-tumor therapy. The deal, valued at up to USD\u202f1.53 billion, grants Gilead exclusive global rights to develop and commercialize the biomarker-driven oncology asset, which has received IND approvals in both the US and China and is ready for immediate global clinical development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57148\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31\" \/>\n<meta property=\"og:description\" content=\"Genhouse Bio (Suzhou) Co., Ltd., a Viva Biotech-incubated company, announced a global collaboration agreement with Gilead Sciences, Inc. (NASDAQ:\u202fGILD) for GH31, its MAT2A-targeting synthetic lethal anti-tumor therapy. The deal, valued at up to USD\u202f1.53 billion, grants Gilead exclusive global rights to develop and commercialize the biomarker-driven oncology asset, which has received IND approvals in both the US and China and is ready for immediate global clinical development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57148\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-14T03:13:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-14T03:13:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57148#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57148\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31\",\"datePublished\":\"2026-02-14T03:13:30+00:00\",\"dateModified\":\"2026-02-14T03:13:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57148\"},\"wordCount\":442,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Genhouse Bio\",\"Gilead Sciences\",\"NASDAQ: GILD\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57148#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57148\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57148\",\"name\":\"Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-14T03:13:30+00:00\",\"dateModified\":\"2026-02-14T03:13:31+00:00\",\"description\":\"Genhouse Bio (Suzhou) Co., Ltd., a Viva Biotech-incubated company, announced a global collaboration agreement with Gilead Sciences, Inc. (NASDAQ:\u202fGILD) for GH31, its MAT2A-targeting synthetic lethal anti-tumor therapy. The deal, valued at up to USD\u202f1.53 billion, grants Gilead exclusive global rights to develop and commercialize the biomarker-driven oncology asset, which has received IND approvals in both the US and China and is ready for immediate global clinical development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57148#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57148\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57148#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31 - Insight, China's Pharmaceutical Industry","description":"Genhouse Bio (Suzhou) Co., Ltd., a Viva Biotech-incubated company, announced a global collaboration agreement with Gilead Sciences, Inc. (NASDAQ:\u202fGILD) for GH31, its MAT2A-targeting synthetic lethal anti-tumor therapy. The deal, valued at up to USD\u202f1.53 billion, grants Gilead exclusive global rights to develop and commercialize the biomarker-driven oncology asset, which has received IND approvals in both the US and China and is ready for immediate global clinical development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57148","og_locale":"en_US","og_type":"article","og_title":"Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31","og_description":"Genhouse Bio (Suzhou) Co., Ltd., a Viva Biotech-incubated company, announced a global collaboration agreement with Gilead Sciences, Inc. (NASDAQ:\u202fGILD) for GH31, its MAT2A-targeting synthetic lethal anti-tumor therapy. The deal, valued at up to USD\u202f1.53 billion, grants Gilead exclusive global rights to develop and commercialize the biomarker-driven oncology asset, which has received IND approvals in both the US and China and is ready for immediate global clinical development.","og_url":"https:\/\/flcube.com\/?p=57148","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-14T03:13:30+00:00","article_modified_time":"2026-02-14T03:13:31+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57148#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57148"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31","datePublished":"2026-02-14T03:13:30+00:00","dateModified":"2026-02-14T03:13:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57148"},"wordCount":442,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Genhouse Bio","Gilead Sciences","NASDAQ: GILD"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57148#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57148","url":"https:\/\/flcube.com\/?p=57148","name":"Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-14T03:13:30+00:00","dateModified":"2026-02-14T03:13:31+00:00","description":"Genhouse Bio (Suzhou) Co., Ltd., a Viva Biotech-incubated company, announced a global collaboration agreement with Gilead Sciences, Inc. (NASDAQ:\u202fGILD) for GH31, its MAT2A-targeting synthetic lethal anti-tumor therapy. The deal, valued at up to USD\u202f1.53 billion, grants Gilead exclusive global rights to develop and commercialize the biomarker-driven oncology asset, which has received IND approvals in both the US and China and is ready for immediate global clinical development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57148#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57148"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57148#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57148"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57148\/revisions"}],"predecessor-version":[{"id":57149,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57148\/revisions\/57149"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}